Review The JAK/STAT signaling pathway: from bench to clinic, 2021, Hu et al.

The JAK/STAT signaling pathway: from bench to clinic
Hu, Xiaoyi; li, Jing; Fu, Maorong; Zhao, Xia; Wang, Wei

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular processes, the JAK/STAT pathway constitutes a rapid membrane-to-nucleus signaling module and induces the expression of various critical mediators of cancer and inflammation. Growing evidence suggests that dysregulation of the JAK/STAT pathway is associated with various cancers and autoimmune diseases.

In this review, we discuss the current knowledge about the composition, activation, and regulation of the JAK/STAT pathway. Moreover, we highlight the role of the JAK/STAT pathway and its inhibitors in various diseases.

Link | PDF (Nature Signal Transduction and Targeted Therapy)

 

This is an in-depth review paper. Posting in relation to upcoming trial on Baricitinib in LC, which is a first generation JAK1/JAK2 inhibitor. In addition to the JAK inhibitors, there are sections on STAT inhibitors, including things like resveratrol, curcumin and other high "consumer-availability" but low bio-availability small molecules.

Here's the section on baricitinib, abbreviated for easy reference —